FindTrial
Sign In

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221919
Enrollment
Unknown
Registered
2012-09-14
Start date
2012-09-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

investigational material(s) Generic name etc : Secukinumab INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration f

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Subjects who complete the full study treatment period of preceding phase III studies. -Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both

Exclusion criteria

Exclusion criteria: -Ongoing use of prohibited psoriasis or non-psoriasis treatments. -Other protocol-defined inclusion/exclusion criteria may apply.

Design outcomes

Primary

MeasureTime frame
AE—

Secondary

MeasureTime frame
PASI 75, IGA—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026